Form 8-K - Current report:
SEC Accession No. 0001641172-25-014103
Filing Date
2025-06-06
Accepted
2025-06-06 17:00:39
Documents
13
Period of Report
2025-06-03
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 60129
2 EX-3.1 ex3-1.htm EX-3.1 7756
  Complete submission text file 0001641172-25-014103.txt   243054

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tnfa-20250603.xsd EX-101.SCH 3017
4 XBRL LABEL FILE tnfa-20250603_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE tnfa-20250603_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3954
Mailing Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS SUITE 249 NEW YORK NY 10036 856-848-8698
TNF Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 251031883
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)